Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 563

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 1B
Chunk 563
---
 of common stock subject to outstanding awards; (3) the grant, purchase, or exercise price
with respect to any award; and (4) the performance goals of an award. In any such case, the Administrator may also provide for a cash
payment to the holder of an outstanding award in exchange for the cancellation of all or a portion of the award, subject to the terms
of the 2023 Omnibus Plan.

The
Administrator may, in connection with any merger, consolidation, acquisition of property or stock, or reorganization, authorize the issuance
or assumption of awards upon terms and conditions we deem appropriate without affecting the number of shares of common stock otherwise
reserved or available under the 2023 Omnibus Plan.

Change
of Control

Upon
a change of control (as defined in the 2023 Omnibus Plan), the successor or surviving corporation may agree to assume some or all outstanding
awards or replace them with the same type of award with similar terms and conditions, without the consent of any participant, subject
to the following requirements:

    ●
    Each
    award that is assumed must be appropriately adjusted, immediately after such change of control, to apply to the number and class
    of securities that would have been issuable to a participant upon the consummation of such change of control had the award been exercised,
    vested, or earned immediately prior to such change of control, and other appropriate adjustment to the terms and conditions of the
    award may be made.

    ●
    If
    the securities to which the awards relate after the change of control are not listed and traded on a national securities exchange,
    then (a) each participant must be provided the option to elect to receive, in lieu of the issuance of such securities, cash in an
    amount equal to the fair value of the securities that would have otherwise been issued, and (b) no reduction may be taken to reflect
    a discount for lack of marketability, minority, or any similar consideration, for purposes of determining the fair value of such
    securities.

    ●
    If
    a participant is terminated from employment without cause, or due to death or disability, or the participant resigns employment for
    good reason (as defined in any award or other agreement between the participant and our company or an affiliate) within two years
    following the change of control, then upon such termination, all of the participant’s awards in effect on the date of such
    termination will vest in